ELECTROPHYSIOLOGIC PROFILE AND EFFICACY OF INTRAVENOUS DOFETILIDE (UK-68,798), A NEW CLASS-III ANTIARRHYTHMIC DRUG, IN PATIENTS WITH SUSTAINED MONOMORPHIC VENTRICULAR-TACHYCARDIA

There is increasing evidence that class III antiarrhythmic agents may be superior to class I agents for the long-term treatment of life-threatening ventricular tachyarrhythmias. This open study evaluated he acute electrophysiologic effects, antiarrhythmic efficacy, and safety of different doses of intravenous dofetilide, a new dass III drug, in 50 patients with sustained monomorphic ventricular tachycardia inducible by programmed electrical stimulation who had previously been unsuccessfully treated with 0 to 7 (median 3) other drugs. Intravenous dofetilide was administered over 60 minutes at he following dose levels: 1.5, 3.0, 6.0, 9.0, and 15.0 mu g/kg. Significant class III activity was apparent at doses of 3.0 to 15.0 mu g/kg, as evidenced by dose-related prolongation of the QTc interval by 13.4% to 14.2%, ventricular effective refractory period by 7.9% to 20.6%, and ventricular functional refractory period by 7.3% to 25.0%. The corresponding mean +/- SD plasma dofetilide concentrations ranged from 1.45 +/- 0.52 to 6.48 +/- 1.31 ng/ml, There was no evidence of reverse use-dependence. At these electrophysiologically active dose levels, intravenous dofetilide suppressed (complete response) or slowed (partial response) inducible ventricular tachycardia in 17 of 41 patients (41%) compared with 0 of 9 patients receiving only 1.5 mu g/kg. The response rate was fairly uniform among the groups receiving 3.0, 6.0, 9.0, and 15.0 mu g/kg. Intravenous dofetilide was hemodynamically well tolerated, Torsades de pointes (which was self-limiting) developed in only 1 patient, who was allocated to receive 15.0 mu g/kg. There were no other proarrhythmic episodes or serious adverse effects. Further evaluation of the therapeutic potential of dofetilide in the management of life-threatening ventricular arrhythmias is justified.